DE60206775D1 - Agonisten für den adenosin a3 rezeptor - Google Patents

Agonisten für den adenosin a3 rezeptor

Info

Publication number
DE60206775D1
DE60206775D1 DE60206775T DE60206775T DE60206775D1 DE 60206775 D1 DE60206775 D1 DE 60206775D1 DE 60206775 T DE60206775 T DE 60206775T DE 60206775 T DE60206775 T DE 60206775T DE 60206775 D1 DE60206775 D1 DE 60206775D1
Authority
DE
Germany
Prior art keywords
adenosine
agonists
receptor
neutropennia
leukopenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60206775T
Other languages
English (en)
Other versions
DE60206775T2 (de
Inventor
Elfatih Elzein
Venkata Palle
Vaibhav Varkhedkar
Jeff Zablocki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Application granted granted Critical
Publication of DE60206775D1 publication Critical patent/DE60206775D1/de
Publication of DE60206775T2 publication Critical patent/DE60206775T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60206775T 2001-08-08 2002-08-06 Agonisten für den adenosin a3 rezeptor Expired - Lifetime DE60206775T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31106901P 2001-08-08 2001-08-08
US311069P 2001-08-08
PCT/US2002/024696 WO2003014137A1 (en) 2001-08-08 2002-08-06 Adenosine a3 receptor agonists

Publications (2)

Publication Number Publication Date
DE60206775D1 true DE60206775D1 (de) 2006-03-02
DE60206775T2 DE60206775T2 (de) 2006-07-20

Family

ID=23205248

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60206775T Expired - Lifetime DE60206775T2 (de) 2001-08-08 2002-08-06 Agonisten für den adenosin a3 rezeptor

Country Status (20)

Country Link
US (1) US20030078232A1 (de)
EP (1) EP1414837B1 (de)
JP (1) JP4357960B2 (de)
KR (1) KR100923888B1 (de)
CN (1) CN1244589C (de)
AT (1) ATE307136T1 (de)
AU (1) AU2002327426C1 (de)
CA (1) CA2456744A1 (de)
DE (1) DE60206775T2 (de)
DK (1) DK1414837T3 (de)
ES (1) ES2247371T3 (de)
HU (1) HUP0401437A3 (de)
IL (2) IL160231A0 (de)
MX (1) MXPA04001185A (de)
NO (1) NO327997B1 (de)
NZ (1) NZ530976A (de)
PL (1) PL368205A1 (de)
RU (1) RU2298557C2 (de)
WO (1) WO2003014137A1 (de)
ZA (1) ZA200401000B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
JP4310109B2 (ja) * 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
SG176313A1 (en) 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
ES2333651T3 (es) * 2002-09-09 2010-02-25 Cv Therapeutics, Inc. Agonistas del receptor de adenosina a3.
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
CA2585581A1 (en) * 2004-11-22 2006-05-26 King Pharmaceuticals Research & Development Inc. Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
JP2008540685A (ja) * 2005-05-19 2008-11-20 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシンレセプターアゴニスト
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2625783A1 (en) * 2005-10-13 2007-04-26 Elfatih Elzein A1 adenosine receptor agonists
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
EP2142546B1 (de) 2007-03-28 2017-06-07 Saniona A/S Purinylderivate und ihre verwendung als kaliumkanalmodulatoren
ZA200905796B (en) * 2007-03-28 2010-10-27 Neurosearch As Purinyl derivatives and their use as potassium channel modulators
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
EP2200615A1 (de) * 2007-10-16 2010-06-30 Gilead Palo Alto, Inc. A3-adenosinrezeptorantagonisten
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
BR112014032501A2 (pt) 2012-06-26 2017-06-27 Saniona Aps composto, e, composição farmacêutica.
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
CA3061893A1 (en) * 2017-05-19 2018-11-22 Alltech, Inc. Selenium containing pharmaceutical agents, compositions, and methods relating thereto
EP3988100A4 (de) * 2019-06-21 2023-07-26 Academy of Military Medical Sciences Adenosinverbindung, pharmazeutisch annehmbares salz oder stereoisomerid davon und verwendung
CN116783196A (zh) * 2020-12-29 2023-09-19 浙江春禾医药科技有限公司 A3腺苷受体激动剂及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists

Also Published As

Publication number Publication date
JP4357960B2 (ja) 2009-11-04
AU2002327426A2 (en) 2003-02-24
JP2005501842A (ja) 2005-01-20
AU2002327426C1 (en) 2008-03-06
ES2247371T3 (es) 2006-03-01
CN1244589C (zh) 2006-03-08
DK1414837T3 (da) 2005-11-07
RU2004106635A (ru) 2005-07-27
ATE307136T1 (de) 2005-11-15
HUP0401437A3 (en) 2007-05-29
AU2002327426B2 (en) 2007-06-14
HUP0401437A2 (hu) 2004-11-29
CN1538972A (zh) 2004-10-20
EP1414837B1 (de) 2005-10-19
EP1414837A1 (de) 2004-05-06
NO20040969L (no) 2004-04-19
KR20040023733A (ko) 2004-03-18
PL368205A1 (en) 2005-03-21
WO2003014137A1 (en) 2003-02-20
RU2298557C2 (ru) 2007-05-10
MXPA04001185A (es) 2005-06-17
DE60206775T2 (de) 2006-07-20
IL160231A0 (en) 2004-07-25
KR100923888B1 (ko) 2009-10-28
ZA200401000B (en) 2004-10-18
NO327997B1 (no) 2009-11-09
CA2456744A1 (en) 2003-02-20
NZ530976A (en) 2005-07-29
IL160231A (en) 2010-11-30
US20030078232A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
DE60206775D1 (de) Agonisten für den adenosin a3 rezeptor
CY1106424T1 (el) Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
ATE305932T1 (de) Rapanycin29-enole
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
BR0214870A (pt) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas e aplicação das mesmas
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
PT1444215E (pt) Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina
SMAP200600024A (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosia
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
DK1450811T3 (da) Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
ATE418555T1 (de) A2a-adenosinrezeptorantagonisten
DK1622908T3 (da) Xanthin-derivater som A2B adenosin-receptor-antagonister
CY1106194T1 (el) Θepαπευτικη αγωγη της δυσκινησιας
MA27094A1 (fr) Derives triazolo-quinoline utiles en tant que ligands recepteurs d'adenosine.
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
WO2004022573A3 (en) Adenosine a3 receptor agonists
DE60206599D1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln
ES2166045T3 (es) Procedimiento para la preparacion de compuestos de 4,6-bis(ariloxi)pirimidina asimetricos.
TR200001622T2 (tr) Asilatlı Hetero-Alisiklik Türevleri
DK1144423T3 (da) Bis-terpyridin-platin(II)-komplekser
RU2000116332A (ru) Антгельминтное средство
DE60203740D1 (de) Luminacine analoge und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition